Fig. 1 · Structure
Documents & Downloads
Trastuzumab deruxtecan
HER2 ADC
Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). This compound combines a humanized anti-HER2 antibody with an enzymatically cleavable peptide-linker and a topoisomerase I inhibitor, enhancing its cytotoxic potential. Trastuzumab deruxtecan is primarily utilized in research focused on HER2-positive breast cancer and gastric cancer, providing insights into targeted therapies and treatment efficacy.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 1826843-81-5 |
| Applications | HER2 ADC |
| Molecular Weight | 153000 (average) |
| Synonyms | DS-8201; DS-8201a |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.